VolitionRx Limited entered into a Waiver and Consent with Lind Global Asset Management XII LLC on September 2, 2026. This agreement waives covenant breaches related to the Company's At-The-Market (ATM) sales exceeding the $10 million annual cap under its Securities Purchase Agreement dated May 15, 2025. Lind consented to treat ATM sales in excess of the limit as Permitted ATM Sales and waived remedies for Events of Default triggered by these sales. The waiver also adjusts the conversion price of the senior secured convertible promissory notes ($9.9 million total principal) and exercise prices of associated warrants based on ATM sales through August 28, 2026. VolitionRx Limited operates in the healthcare diagnostics industry, developing molecular diagnostic tests for cancer detection.
